Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Ácido Oxónico/uso terapéutico , Neoplasias Pancreáticas/tratamiento farmacológico , Tegafur/uso terapéutico , Combinación de Medicamentos , Humanos , Metástasis de la Neoplasia , Estadificación de Neoplasias , Ácido Oxónico/efectos adversos , Neoplasias Pancreáticas/mortalidad , Neoplasias Pancreáticas/patología , Tegafur/efectos adversosAsunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Ácido Oxónico/farmacocinética , Ácido Oxónico/uso terapéutico , Tegafur/farmacocinética , Tegafur/uso terapéutico , 2-Piridinilmetilsulfinilbencimidazoles/administración & dosificación , Administración Oral , Antiulcerosos/administración & dosificación , Antimetabolitos Antineoplásicos/sangre , Antimetabolitos Antineoplásicos/farmacocinética , Área Bajo la Curva , Disponibilidad Biológica , Ensayos Clínicos como Asunto , Dihidrouracilo Deshidrogenasa (NADP)/sangre , Combinación de Medicamentos , Ayuno , Fluorouracilo/análogos & derivados , Fluorouracilo/metabolismo , Alimentos , Determinación de la Acidez Gástrica , Semivida , Humanos , Concentración de Iones de Hidrógeno , Ácido Oxónico/sangre , Ácido Oxónico/metabolismo , Pantoprazol , Piridinas/metabolismo , Piridinas/farmacocinética , Piridinas/uso terapéutico , Tegafur/sangre , Tegafur/metabolismo , Triazinas/metabolismo , Uracilo/análogos & derivados , Uracilo/metabolismo , beta-Alanina/análogos & derivados , beta-Alanina/metabolismoRESUMEN
The small molecule receptor tyrosine kinase (RTK) inhibitor SU5416 targets the vascular endothelial growth factor receptor 2 and the stem cell factor receptor c-kit. Herein is described the successful treatment of a 65-year-old woman with SU5416, in second relapse of acute myeloid leukemia (AML) and refractory toward standard chemotherapy regimens. After 12 weeks of treatment with SU5416, the blast cell counts (blood and bone marrow) decreased to undetectable levels and the peripheral blood cell counts normalized with the exception of the platelet count (50-80 x 10(9)/L [50-80 x 10(3)/microL]). The duration of the remission is longer than 4 months during maintenance therapy with SU5416. Microvessel density in the patient's bone marrow dropped from 33.4 to 12.3 microvessels/x500-field 8 weeks after SU5416 administration and remains in the normal range. This is the first report of a stable remission achieved after administration of the RTK inhibitor SU5416 in a patient with AML relapse.
Asunto(s)
Indoles/administración & dosificación , Leucemia Mieloide/tratamiento farmacológico , Pirroles/administración & dosificación , Enfermedad Aguda , Inhibidores de la Angiogénesis/administración & dosificación , Antineoplásicos/administración & dosificación , Células de la Médula Ósea/química , Endotelio Vascular/química , Endotelio Vascular/citología , Femenino , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas Receptoras/efectos de los fármacos , Proteínas Tirosina Quinasas Receptoras/metabolismo , Receptores de Factores de Crecimiento/efectos de los fármacos , Receptores de Factores de Crecimiento/metabolismo , Receptores de Factores de Crecimiento Endotelial Vascular , Inducción de Remisión/métodosRESUMEN
BACKGROUND: Ularitide is a member of the natriuretic peptide family. This hormone exhibits an N-terminal extension by four amino acids compared with atrial natriuretic peptide. Ularitide was shown to exert strong diuretic and natriuretic effects when infused intravenously. Its main action sites are the glomerulum, inducing preglomerular vasodilation and postglomerular vasoconstriction and thereby elevating the glomerular filtration rate, and the tubular system inhibiting Na(+)-reabsorption. In initial uncontrolled clinical trials, this peptide was shown to have beneficial effects in patients suffering from oliguric acute renal failure. METHODS: We conducted a double-blind, placebo-controlled, multicenter, dose-finding trial recruiting 176 patients randomized into 4 different Ularitide doses groups (U5, U20, U40, and U80 ng/kg/min) and a placebo group (U0). Ularitide/placebo infusion was performed for 5 days with half the originally infused dose on day 5. The primary objective of the study was to test various doses of Ularitide in patients suffering from oliguric acute renal failure to avoid mechanical renal replacement therapy during the first 12 hours. FINDINGS: The results indicate that Ularitide does not reduce the incidence of mechanical renal replacement therapy compared with placebo-treated patients during the first 12 h of treatment (U0: 36 (20), U5: 35 (11), U20: 36 (9), U40: 28 (8), U80: 41 (12), (% (n) (p = 0.87)). Diuresis increased in the Ularitide-treated groups and the placebo group after onset of infusion and did not show any significant difference in the first 12 h collection period (U0: 576, U5: 514, U20: 500, U40: 360, U80: 158 ML/12h (Median), (p = 0.16)). INTERPRETATION: In summary, the incidence of mechanical renal replacement therapy in critically ill patients suffering from oliguric acute renal failure could not be altered positively by Ularitide administration according to our protocol. Further prospective clinical trials are needed to answer the question whether a different patient collective or a prophylactic administration of Ularitide are more promising approaches in the clinical setting of oliguric acute renal failure.
Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , Factor Natriurético Atrial/uso terapéutico , Diuréticos/uso terapéutico , Fragmentos de Péptidos/uso terapéutico , Lesión Renal Aguda/complicaciones , Lesión Renal Aguda/fisiopatología , Anciano , Factor Natriurético Atrial/administración & dosificación , Factor Natriurético Atrial/efectos adversos , Presión Sanguínea , Nitrógeno de la Urea Sanguínea , Enfermedades Cardiovasculares/etiología , Creatinina/sangre , Creatinina/metabolismo , Diuréticos/administración & dosificación , Diuréticos/efectos adversos , Método Doble Ciego , Femenino , Humanos , Hipotensión/etiología , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/efectos adversos , Terapia de Reemplazo Renal , Factores de TiempoRESUMEN
OBJECTIVE: To investigate whether a weekly 1500 IU/kg dose of recombinant human erythropoietin (rhEPO) is more effective than a dose of 750 IU/kg/week in preventing anemia and reducing the transfusion need in infants with birth weights less than 1000 gm. STUDY DESIGN: In a randomized, double-blind, multicenter trial, 184 infants with birth weights between 500 and 999 gm were treated with either rhEPO 750 (low-dose group) or 1500 IU/kg/week (high-dose group) from day 3 of life until 37 weeks' corrected age. RESULTS: Thirty-two percent of the infants in each group did not receive any transfusion during the treatment period. The total volume of erythrocytes received was similar in each group. The success rate, defined as no transfusion needed and hematocrit value 0.30 L/L or greater, was 27.6% in the low-dose and 29.5% in the high-dose group (p = 0.96). CONCLUSION: Doubling the rhEPO dose of 750 IU/kg/week is not indicated in infants with birth weights less than 1000 gm.
Asunto(s)
Anemia/prevención & control , Eritropoyetina/administración & dosificación , Recién Nacido de muy Bajo Peso , Transfusión Sanguínea/estadística & datos numéricos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Esquema de Medicación , Femenino , Edad Gestacional , Hematócrito , Humanos , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/prevención & control , Recién Nacido de muy Bajo Peso/sangre , Hierro/uso terapéutico , Masculino , Proteínas RecombinantesRESUMEN
We estimated the efficacy of oral iron therapy during treatment with rhEPO in patients undergoing cardiac surgery who were contraindicated for autologous blood donation. Seventy-six patients were enrolled in this double-blind, placebo-controlled trial and assigned to the 2 treatment groups (5x500 U/kg body weight rhEPO or placebo intravenously over 14 d before surgery). During the treatment period all patients received 300 mg Fe2+ (iron glycine sulfate) orally per day. rhEPO therapy produced significant increases in hemoglobin concentration (Hb), reticulocyte count, hematocrit (Hct) and the hypochromic red blood cells (HRBC), and a decrease in transferrin saturation (41%) compared to the placebo group before surgery. However, the preoperative increase in HRBC was independent of the baseline ferritin and even correlated positively with the preoperative increase in Hct (r=0.47, p<0.01). In rhEPO patients there were inverse correlations between baseline serum iron and the preoperative increases in Hb (r=-0.39, p<0.05), Hct (r=-0.50, p<0.01) and HRBC (r=-0.53, p<0.001). With this treatment regimen the HRBC appear to reflect the degree of erythropoietic stimulation rather than functional iron deficiency. The preoperative increases in reticulocytes, HRBC and Hb/Hct in patients with ferritin <100 mg/l or transferrin saturation <16% showed no significant difference compared to their complementary groups. The preoperative decrease in storage iron and the inverse correlation between the baseline ferritin and the preoperative change in ferritin (r=-0.94, p<0.0001) in the rhEPO group indicate that the iron requirement for hemoglobin synthesis is probably covered by the breakdown of stored iron and an increase in the rate of absorption of orally administered Fe2+. Intravenous rhEPO treatment with 5x500 U/kg body weight in combination with 300 mg oral Fe2+/d given over 14 d before surgery is a suitable regimen to increase Hb by about 1.61 g/dl and Hct by 0.06.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Suplementos Dietéticos , Eritropoyetina/uso terapéutico , Hierro/uso terapéutico , Administración Oral , Terapia Combinada , Método Doble Ciego , Humanos , Proteínas Recombinantes , Recuento de Reticulocitos/efectos de los fármacos , Resultado del TratamientoRESUMEN
The changes in the red cell and reticulocyte distribution widths during preoperative treatment with recombinant human erythropoietin (rhEPO) were evaluated in a double-blind, placebo-controlled trial in cardiac surgery patients. The increases in the reticulocyte count, in the hemoglobin and in all distribution widths are the expression of the marked preoperative stimulation of erythropoiesis in the patients treated with rhEPO. Only placebo patients with a hemoglobin < or = 7.5 mmol/l or a transferrin > 4.0 g/l at baseline showed an increase in the red cell distribution width or in the reticulocyte hemoglobin distribution width on oral iron therapy alone. While the reticulocyte count and the distribution widths of red cells in the rhEPO patients decreased postoperatively, only the increases in the distribution widths of reticulocytes after the second postoperative day indicate that stimulation oferythropoiesis had taken place. In patients with a low hemoglobin or a high transferrin the rhEPO therapy should be preceded by iron therapy in order to raise the hemoglobin level and reduce the cost of treatment.
Asunto(s)
Recuento de Eritrocitos , Eritropoyesis , Eritropoyetina/uso terapéutico , Recuento de Reticulocitos , Procedimientos Quirúrgicos Torácicos , Adulto , Anciano , Método Doble Ciego , Femenino , Humanos , Hierro/metabolismo , Masculino , Persona de Mediana Edad , Proteínas Recombinantes , Factores de TiempoRESUMEN
We evaluated the changes in reticulocyte maturity fractions and indices, as measured by flow cytometry, during preoperative treatment with recombinant human erythropoietin (epoetin beta) in cardiac surgery patients. A total of 72 patients was enrolled in this double-blind, randomized, placebo-controlled clinical trial and assigned to the two treatment groups (5 x 500 U/kg bodyweight epoetin beta or placebo intravenously over 14 days preoperatively). Therapy with epoetin beta produced continuous increases in hematocrit/hemoglobin, in the most mature fraction of reticulocytes (LR), and in reticulocyte count. In the first treatment week there were parallel increases in the fraction of most immature reticulocytes (HR) and in the reticulocyte mean cell volume. During the second week of treatment the reticulocyte mean cell hemoglobin content (CHr) decreased, but CHr was independent of all iron parameters, affecting neither the reticulocyte fractions nor the hematocrit/hemoglobin increase. The total preoperative rise in hematocrit correlated with the rises in LR fraction (P = 0.0270) and reticulocyte count (P = 0.0486) during the first week of treatment. Whereas in the epoetin beta patients the preoperative change in HR fraction showed negative correlations with transferrin saturation at baseline (P = 0.0058) and with the preoperative change in iron (P = 0.0113), the preoperative change in the LR fraction correlated positively with transferrin at baseline (P = 0.0115). Postoperatively, the reticulocyte parameters revealed that the onset of increased stimulation of erythropoiesis did not occur in the placebo patients until the second postoperative day, whereas erythropoietic activity in the epoetin beta patients was much higher during the postoperative period as well, as a result of the preoperative stimulation of erythropoiesis. The reticulocyte parameters measured by flow cytometry permitted an objective analysis of erythropoietic activity during treatment with epoetin beta and in all patients postoperatively. Further studies in various types of epoetin beta therapy are needed in order to clarify the value of these reticulocyte parameters for identification of iron deficiency and optimization of epoetin beta treatment regimen.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Eritropoyesis/efectos de los fármacos , Eritropoyetina/uso terapéutico , Reticulocitos/citología , Hematócrito , Humanos , Hierro/sangre , Análisis Multivariante , Proteínas Recombinantes , Análisis de Regresión , Recuento de Reticulocitos , Factores de Tiempo , Transferrina/metabolismoRESUMEN
In a double-blind, randomized, placebo-controlled trial we evaluated the effects of the administration of recombinant human erythropoietin (5 x 500 U epoetin beta/kg body weight intravenously over a 14-day period before surgery) in patients undergoing cardiac surgery and in whom autologous blood donation was contraindicated on platelet count, platelet distribution width, mean platelet volume (MPV), and certain hemostaseologic parameters. All patients received 3 x 70 IU heparin/kg per day s.c. from 2 days before operation. No thromboembolic events were associated with epoetin beta therapy during the study period. The thrombocytic parameters showed no significant changes in the placebo group before surgery, and the preoperative hematocrit increase in the epoetin beta group was accompanied with an MPV drop (in contrast to the known MPV rise in recombinant human erythropoietin-treated patients with uremia) by a mean of 0.85 fl and a platelet distribution width rise by 3.3% without a significant change in platelet count. In the epoetin beta group the coagulation time (K) of thromboelastogram (TEG) showed an increase from 4.8 to 5.4 minutes by the seventh study day and after the initiation of heparin therapy a further increase to 7.5 minutes. The higher preoperative K increase in the epoetin beta group may partly be a result of the MPV reduction, because smaller platelets are less reactive, a fact underlined by the negative correlation between the preoperative changes of MPV and reaction time of TEG (r = -0.58, p = 0.0148). In contrast, in the placebo group the K of TEG increased only after the start of heparin therapy (from 5.1 to 6.4 minutes). The significant drop in MPV in the epoetin beta group and the higher increase in K of TEG and the other investigated hemostatic parameters do not suggest any increased thromboembolic risk during the preoperative epoetin beta therapy. Therefore this treatment seems to be a safe way for increasing mean hematocrit by approximately 0.06 within the normal range and reducing the homologous blood requirement in patients undergoing elective cardiac surgery.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Eritropoyetina/farmacología , Activación Plaquetaria/efectos de los fármacos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Transfusión Sanguínea , Método Doble Ciego , Femenino , Hematócrito , Hemostasis Quirúrgica , Humanos , Periodo Intraoperatorio , Masculino , Persona de Mediana Edad , Placebos , Recuento de Plaquetas , Premedicación , Proteínas Recombinantes , Factores de Riesgo , Tromboembolia/inducido químicamente , Tromboembolia/epidemiologíaRESUMEN
We evaluated in a double-blind randomized study the effect of epoetin beta (recombinant human erythropoietin) therapy on oxygen status in patients undergoing cardiac surgery who were contraindicated for autologous blood donation. All 76 patients enrolled in this study were randomized to the two treatment groups (5 x 500 U epoetin beta or placebo/kg body weight intravenously over a 14-day period before surgery) and received 300 mg Fe2+ per day orally before surgery. Before and after surgery the lactate level and the following parameters according to the oxygen status algorithm by Siggaard-Andersen were evaluated: arterial oxygen tension (PaO2), effective hemoglobin concentration (ceHb), arterial oxygen saturation (SaO2), oxygen half saturation tension (p50), red cell 2.3 diphosphoglycerate (2.3 DPG), arterial total oxygen concentration (ctO2), concentration of extractable oxygen (cx), and oxygen compensation factor (Qx). Therapy with epoetin beta led to increases in ceHb, PaO2, ctO2, and cx and to a decrease in Qx before surgery (p < 0.05 for PaO2, p < 0.0001 for the other parameters vs placebo). The cx in patients who received epoetin beta rose by approximately 20%, thus indicating a considerable improvement in O2 delivery. In patients receiving placebo the hemoximetric parameters remained outside the normal limits at all times after surgery, but in the epoetin beta group PaO2, ctO2, cx, and Qx returned almost to their baseline values by the second or fifth postoperative day, even though the frequency of transfusions was significantly higher in the placebo group. Whereas p50 and 2.3 DPG fell in the placebo group after surgery, these two parameters were significantly higher in the epoetin beta group and led to a further increase in cx (from 24% to 38%) versus the placebo group as a result of the right shift in the hemoglobin O2-binding curve. The postoperative incidence and severity of lactic acidosis were higher in the placebo group. Preoperative epoetin beta therapy is a safe way of providing increased extractable O2 (by 24% to 38%) and decreasing the risk of lactic acidosis after surgery. This therapy has a more favorable effect on the O2 binding curve than the transfusion of erythrocyte concentrate and enhances the effect of epoetin beta therapy on the postoperative oxygen status.
Asunto(s)
Algoritmos , Procedimientos Quirúrgicos Cardíacos , Eritropoyetina/uso terapéutico , Consumo de Oxígeno/efectos de los fármacos , Oxígeno/sangre , Acidosis/prevención & control , Método Doble Ciego , Femenino , Humanos , Ácido Láctico/sangre , Masculino , Persona de Mediana Edad , Oxígeno/análisis , Cuidados Preoperatorios/métodos , Proteínas RecombinantesRESUMEN
In a double-blind, randomized, placebo-controlled trial, we evaluated the ability of epoetin beta (recombinant human erythropoietin) to avoid allogeneic blood transfusions (ABT) and the associated risks in patients undergoing primary elective open-heart surgery and in whom autologous blood donation (ABD) was contraindicated. Seventy-six patients overall were enrolled onto the trial and were randomly assigned to the two treatment groups, 5 x 500 U/kg body weight (BW) epoetin beta or placebo intravenously over 14 days preoperatively. All patients received 300 mg Fe2+ orally per day during the treatment period. Preoperatively, the mean hemoglobin increase was 1.50 g/dL greater in epoetin beta patients than in placebo patients (95% confidence interval, 1.10 to 1.90 g/dL), allowing a rapid return to the baseline value by the seventh postoperative day in most epoetin beta patients. The mean volume of blood collected by intraoperative isovolemic hemodilution was 562 mL (red blood cell mass, 274 mL) in the epoetin beta group and 218 mL (red blood cell mass, 94 mL) in the placebo group, respectively. Only four patients (11%) in the epoetin beta group received an ABT, compared with 19 (53%) in the placebo group (P = .0003). Epoetin beta was most useful in patients with a perioperative blood loss greater than 750 mL, in those with a baseline hematocrit value less than 0.42, and in those aged > or = 60 years. The iron supplementation proved adequate despite the fact that a significant decrease in ferritin (median, 48.1%) and transferrin saturation (median, 40.5%) was observed in epoetin beta patients preoperatively. No influence of epoetin beta therapy on blood pressure, laboratory safety variables, or the frequency of specific adverse events was observed. Intravenous epoetin beta treatment of 5 x 500 U/kg BW in combination with 300 mg Fe2+ orally per day administered over 14 days preoperatively is an adequate therapy for increasing mean hemoglobin levels by approximately 1.50 g/dL and reducing the allogeneic blood requirement in patients undergoing elective open-heart surgery and in whom ABD is contraindicated.
Asunto(s)
Pérdida de Sangre Quirúrgica/prevención & control , Transfusión Sanguínea , Procedimientos Quirúrgicos Cardíacos , Eritropoyetina/administración & dosificación , Femenino , Humanos , Inyecciones Intravenosas , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificaciónRESUMEN
Biochemical markers of bone turnover have been employed in phase II dose-finding trials to determine the therapeutic window of the highly potent bisphosphonate ibandronate. For intravenous dose finding in metastatic bone disease 158 patients with breast cancer were treated by single bolus injection of up to 3.0 mg and by single infusion of 4 and 6 mg of ibandronate. In the oral double-blind dose-finding trial, 108 patients received up to 50 mg of ibandronate or placebo once daily for 28 days. For dose-finding in osteoporosis 126 postmenopausal women with osteoporosis were treated in a double-blind trial by four injections of up to 2.0 mg of ibandronate or placebo every 3 months. In the phase II dose-finding trial, 180 postmenopausal women with osteoporosis received up to 5 mg of ibandronate or placebo daily for 12 months. During these trials, the bone resorption markers urinary Ca, pyridinoline (Pyd), deoxypyridinoline (Dpd), type I collagen cross-linked N-telopeptide and type I collagen cross-linked C-telopeptide revealed clear dose-dependent responses in accordance with the appropriate dose of ibandronate. The bone formation markers serum osteocalcin, carboxy-terminal propeptide of type I collagen and bone-specific alkaline phosphatase demonstrated also dose-dependent changes in long-term treatment. Thus, for dose finding and monitoring of ibandronate treatment in osteoporosis and in patients with malignant metastatic bone disease urinary type I collagen cross-linked N-telopeptide and C-telopeptide are the most responsive biochemical markers of bone resorption. For bone formation monitoring serum osteocalcin and serum bone-specific alkaline phosphatase should be employed.
Asunto(s)
Biomarcadores , Huesos/química , Difosfonatos/administración & dosificación , Osteoporosis Posmenopáusica/tratamiento farmacológico , Osteoporosis Posmenopáusica/metabolismo , Absorciometría de Fotón , Administración Oral , Adulto , Fosfatasa Alcalina/análisis , Aminoácidos/orina , Biomarcadores/sangre , Biomarcadores/orina , Resorción Ósea/tratamiento farmacológico , Huesos/enzimología , Calcitriol/sangre , Creatinina/orina , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Humanos , Ácido Ibandrónico , Inyecciones Intravenosas , Persona de Mediana Edad , Osteocalcina/análisis , Hormona Paratiroidea/sangre , Placebos , Procolágeno/análisisRESUMEN
UNLABELLED: Two clinical studies were conducted to investigate the efficacy and safety of epoetin beta in 266 [corrected] anemic predialysis patients. Epoetin beta was administered subcutaneously either daily or thrice weekly. Mean duration of treatment was 211 days (interquartile range: 105 to 350 days). RESULTS: Renal anemia could be corrected and the regular transfusion need could be eliminated in all patients. There was no difference in the dose requirement per week between daily and thrice weekly administration of epoetin beta. Regarding the entire study population, there was no acceleration of the progression of renal failure during epoetin beta treatment nor were there any notable changes in laboratory values other than retention values. Epoetin beta was safe and well tolerated; the most important adverse event was the development or aggravation of hypertension.
Asunto(s)
Anemia/terapia , Eritropoyetina/uso terapéutico , Fallo Renal Crónico/complicaciones , Adulto , Anciano , Anemia/etiología , Anemia/metabolismo , Transfusión Sanguínea , Terapia Combinada , Creatinina/metabolismo , Progresión de la Enfermedad , Método Doble Ciego , Femenino , Humanos , Inyecciones Subcutáneas , Compuestos de Hierro/uso terapéutico , Fallo Renal Crónico/metabolismo , Fallo Renal Crónico/terapia , Masculino , Metaloproteínas/metabolismo , Persona de Mediana EdadRESUMEN
Members of Jehovah's Witnesses refuse blood transfusions and blood products under any circumstances. Because of an improvement in blood salvage techniques in our centre, they are not excluded from open-heart surgery. In recent years recombinant human erythropoietin (rhEPO) has been applied to correct perioperative anemia in these patients. METHODS. Seventeen members of Jehovah's Witnesses who were more than 18 years of age were operated on using various blood salvage technique, e.g., haemoseparation and a high dose of Aprotinin. We present the first three patients treated with 4 x 500 U of i.v. rhEPO/kg body wt. given within 11 days preoperatively. Thirteen of the patients operated on had elevated preoperative risk factors, for instance poor left ventricle, severe aortic valve stenosis, metabolic syndrome, age older than 70 years, etc. In other centres that perform cardiac operations on members of Jehovah's Witnesses, these risk factors represent contraindications for open-heart surgery in these patients. RESULTS. Patients with rhEPO treatment showed a preoperative hematocrit increase of 7 Vol.% within 10 days and no postoperative complications. At the 6th postoperative hour the hematocrit returned to the starting values; in patients without rhEPO, however, the hematocrit generally had not increased to preoperative values even by the 8th day after operation. In 9 patients with preoperative elevated risk factors and a postoperative relative decrease in hematocrit below 33% we observed an uncomplicated postoperative period. Four patients with these risk factors, a pronounced decrease in hematocrit and blood loss postoperatively had various severe complications. CONCLUSIONS. Preoperative treatment with a high dose of rhEPO to enhance the hematocrit and maturity by precursor red blood cells in patients with a hematocrit below 45 Vol.% is a possibility to compensate for the blood loss perioperatively and to avoid complications from a decrease in oxygen transport capacity. The anaemia and high blood loss postoperatively are the main causes for a slightly elevated operation risk in members of Jehovah's Witnesses in all heart centres that perform cardiac operations on these patients. Nevertheless, Jehovah's Witnesses should be not excluded from cardiac operations, since open-heart surgery without use of homologous blood is becoming a routine procedure.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Cristianismo , Anciano , Anciano de 80 o más Años , Transfusión de Sangre Autóloga , Eritropoyetina/uso terapéutico , Femenino , Máquina Corazón-Pulmón , Hematócrito , Humanos , Complicaciones Intraoperatorias/terapia , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/uso terapéutico , Factores de Riesgo , Factores de TiempoRESUMEN
The aims of this clinical study were to compare the maintenance doses for intravenous (i.v.) and subcutaneous (SC) administration of recombinant human erythropoietin (rhEPO) and to investigate whether there is any difference in the increase of the packed cellular volume (PCV) per week under i.v. and SC administration of rhEPO from two production sites (Genetics Institute, Cambridge, USA; and Boehringer Mannheim, Penzberg, Germany). A total of 90 patients suffering from end-stage renal disease were included in the study. All patients had already been treated for at least 6 months with chronic hemodialysis. The study was carried out as a randomized, multicenter parallel group comparison study with a 1-week pretreatment phase, a subsequent 8-week double-blind phase, and a final open phase. The final open phase consisted of a correction phase and a maintenance phase. The production site had no influence on the PCV increase per week, and there were no differences with respect to tolerability. The median rhEPO dose required to maintain the target PCV of 30 to 35 vol.% was 33 U/kg body weight three times a week in the i.v. group compared with 22 U/kg in the SC group (i.e., an average of 30% less with SC administration). Development or aggravation of hypertension under rhEPO therapy was observed, especially during the correction phase and more frequently in the SC group than in the i.v. group. During the maintenance phase, there was no essential difference between the two groups.
Asunto(s)
Eritropoyetina/administración & dosificación , Adulto , Anciano , Análisis de Varianza , Anemia/sangre , Anemia/etiología , Anemia/terapia , Método Doble Ciego , Eritropoyetina/efectos adversos , Eritropoyetina/biosíntesis , Femenino , Alemania , Hematócrito , Humanos , Hipertensión/etiología , Inyecciones Intravenosas , Inyecciones Subcutáneas , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/biosíntesis , Diálisis RenalRESUMEN
BACKGROUND: Anemia of prematurity is characterized by low reticulocyte counts and inadequate erythropoietin response, for which many very-low-birth-weight infants receive multiple blood transfusions. We investigated whether early treatment of such infants with recombinant human erythropoietin would reduce their need for transfusions. METHODS: We performed a controlled, blinded trial in 241 infants with very low birth weights at 12 centers in six European countries. When three days old, the infants were randomly assigned either to the epoetin group or to the control group. Those in the epoetin group received 250 IU of epoetin beta per kilogram of body weight subcutaneously three times a week from day 3 to day 42 (for a total of 17 doses); those in the control group did not receive this drug. Infants in both groups received oral iron (2 mg per day) from day 14 onward. RESULTS: The control infants needed a mean of 1.25 transfusions each, as compared with 0.87 transfusion for epoetin-treated infants (P = 0.013). The median cumulative volume of blood transfused per kilogram per day was 0.41 ml in the control group (first quartile, 0 ml; third quartile, 0.8 ml) and 0.09 ml in the epoetin group (first quartile, 0 ml; third quartile, 0.8 ml) (P = 0.044). The rate of success, defined as an absence of need for transfusions and a hematocrit that never fell below 32 percent, was 4.1 percent in the control group and 27.5 percent in the epoetin group (P = 0.008). Epoetin was most beneficial in boys with birth weights of 1200 g or more and a base-line hematocrit of 48 percent or more. No toxic effects were observed in the epoetin group; as compared with the control group, the epoetin group had an increased incidence of septicemia (14 vs. 7 episodes, P not significant) and reduced weight gain (520 vs. 571 g, P = 0.02). CONCLUSIONS: Infants with very low birth weights have less need of transfusions if given epoetin beta during the first six weeks of life (250 IU per kilogram three times a week). We recommend early epoetin treatment for all such infants, but further studies of nutrition and iron supplementation during treatment are needed.
Asunto(s)
Anemia Neonatal/prevención & control , Transfusión Sanguínea , Eritropoyetina/uso terapéutico , Recién Nacido de Bajo Peso , Enfermedades del Prematuro/prevención & control , Anemia Neonatal/terapia , Análisis Costo-Beneficio , Eritropoyetina/efectos adversos , Eritropoyetina/economía , Femenino , Humanos , Recién Nacido , Enfermedades del Prematuro/terapia , Inyecciones Subcutáneas , Hierro/uso terapéutico , Masculino , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/economía , Proteínas Recombinantes/uso terapéutico , Resultado del TratamientoRESUMEN
In a controlled European multicenter study, clinical tolerance of subcutaneously administered recombinant human erythropoietin (rh-EPO) therapy and its influence on the course of illness in 362 hemodialyzed patients (162 males, 200 females) from 16 European dialysis centers was studied. Of these, 181 patients served as a control group in the first year and received rh-EPO therapy in the second year. Of the 837 adverse events that occurred, 277 were classified as serious and 560 as nonserious. Thirty-two deaths have been reported for the study population: 18 in the control group and 14 in the therapy group. The individual analysis of the serious adverse events including death demonstrates a protective effect of rh-EPO on the high-risk cardiovascular situation of dialysis patients. Hypertension was no problem, and under rh-EPO therapy an increase in resistance to infection was observed. Subcutaneous rh-EPO treatment might have an even better safety profile than intravenous application.